JP2021036883A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021036883A5 JP2021036883A5 JP2020186004A JP2020186004A JP2021036883A5 JP 2021036883 A5 JP2021036883 A5 JP 2021036883A5 JP 2020186004 A JP2020186004 A JP 2020186004A JP 2020186004 A JP2020186004 A JP 2020186004A JP 2021036883 A5 JP2021036883 A5 JP 2021036883A5
- Authority
- JP
- Japan
- Prior art keywords
- car
- nucleic acid
- cells
- domain
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 230000001086 cytosolic effect Effects 0.000 claims 3
- 210000002865 immune cell Anatomy 0.000 claims 3
- 102000002467 interleukin receptors Human genes 0.000 claims 3
- 108010093036 interleukin receptors Proteins 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims 2
- 102000004527 Interleukin-21 Receptors Human genes 0.000 claims 2
- 108010017411 Interleukin-21 Receptors Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 101001004391 Drosophila melanogaster Protein jim lovell Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 230000005809 anti-tumor immunity Effects 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 102000027411 intracellular receptors Human genes 0.000 claims 1
- 108091008582 intracellular receptors Proteins 0.000 claims 1
- 230000004068 intracellular signaling Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 108091006106 transcriptional activators Proteins 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562115527P | 2015-02-12 | 2015-02-12 | |
| US62/115,527 | 2015-02-12 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017541919A Division JP6846352B2 (ja) | 2015-02-12 | 2016-02-11 | キメラ抗原受容体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021036883A JP2021036883A (ja) | 2021-03-11 |
| JP2021036883A5 true JP2021036883A5 (enExample) | 2021-10-28 |
Family
ID=56614021
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017541919A Active JP6846352B2 (ja) | 2015-02-12 | 2016-02-11 | キメラ抗原受容体 |
| JP2020186004A Pending JP2021036883A (ja) | 2015-02-12 | 2020-11-06 | キメラ抗原受容体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017541919A Active JP6846352B2 (ja) | 2015-02-12 | 2016-02-11 | キメラ抗原受容体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10336810B2 (enExample) |
| EP (1) | EP3256496B1 (enExample) |
| JP (2) | JP6846352B2 (enExample) |
| KR (1) | KR102607152B1 (enExample) |
| CA (1) | CA2974998C (enExample) |
| ES (1) | ES2857998T3 (enExample) |
| WO (1) | WO2016127257A1 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2974998C (en) | 2015-02-12 | 2022-04-26 | Takara Bio Inc. | Chimeric antigen receptors |
| EP3770168A1 (en) | 2015-05-18 | 2021-01-27 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| GB201518816D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| US12202856B2 (en) * | 2016-05-19 | 2025-01-21 | The General Hospital Corporation | Tethered interleukin-2 to its receptor IL-2RBETA, a platform to enhance natural killer and regulatory T cell activity |
| WO2018026953A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| US12350349B2 (en) | 2016-08-03 | 2025-07-08 | Washington University | Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors |
| US20190119636A1 (en) | 2017-10-23 | 2019-04-25 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
| BR112019007100A2 (pt) | 2016-10-07 | 2019-06-25 | Tcr2 Therapeutics Inc | composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão |
| CN110177803A (zh) | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重新编程的组合物和方法 |
| CA3045667A1 (en) * | 2016-12-13 | 2018-06-21 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo |
| AU2019227979B2 (en) * | 2018-03-02 | 2024-09-05 | Allogene Therapeutics, Inc. | Inducible chimeric cytokine receptors |
| WO2019175328A1 (en) | 2018-03-14 | 2019-09-19 | Imba - Institut Für Molekulare Biotechnologie Gmbh | Bh4pathwayactivationandusethereoffortreatingcancer |
| CA3091490A1 (en) | 2018-04-27 | 2019-10-31 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Rapamycin resistant cells |
| WO2019210280A1 (en) * | 2018-04-27 | 2019-10-31 | Casebia Therapeutics Limited Liability Partnership | Anti-bcma car-t-cells for plasma cell depletion |
| CN110615843B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种包含第三信号受体的嵌合抗原受体及其应用 |
| GB201814203D0 (en) * | 2018-08-31 | 2018-10-17 | King S College London | Engineered regulatory t cell |
| EP3848387A4 (en) * | 2018-09-05 | 2022-06-22 | Kong, Seogkyoung | CHIMERIC ANTIGEN RECEPTOR FOR SOLID TUMOR AND T-CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR |
| KR20210132668A (ko) * | 2019-02-21 | 2021-11-04 | 아르벨 리미티드 | 인공 면역감시 키메라 항원 수용체(ai-car) 및 이를 발현하는 세포 |
| IL285941B1 (en) | 2019-03-01 | 2026-08-01 | Allogene Therapeutics Inc | Cytokine chemoreceptors bearing the PD-1 ECTODOMAIN |
| IL328846A (en) | 2019-03-01 | 2026-08-01 | Allogene Therapeutics Inc | Constitutively active chimeric cytokine receptors and compounds comprising them for the treatment of cancer and autoimmune diseases |
| GB201911187D0 (en) * | 2019-08-05 | 2019-09-18 | Autolus Ltd | Receptor |
| GB201912515D0 (en) * | 2019-08-30 | 2019-10-16 | King S College London | Engineered regulatory T cell |
| BR112022003553A2 (pt) | 2019-08-30 | 2022-05-24 | Allogene Therapeutics Inc | Receptores de citocina quiméricos compreendendo domínios de ligação a tgf beta |
| WO2021046261A1 (en) * | 2019-09-05 | 2021-03-11 | Poseida Therapeutics, Inc. | Allogeneic cell compositions and methods of use |
| CN110717956B (zh) * | 2019-09-30 | 2023-06-20 | 重庆大学 | 一种有限角投影超像素引导的l0范数最优化重建方法 |
| TWI717880B (zh) * | 2019-10-24 | 2021-02-01 | 中國醫藥大學附設醫院 | Hla-g特異性嵌合抗原受體、核酸、hla-g特異性嵌合抗原受體表達質體、表達hla-g特異性嵌合抗原受體細胞、其用途以及用於治療癌症之醫藥組合物 |
| KR20220131529A (ko) * | 2020-01-14 | 2022-09-28 | 신테카인, 인크. | 변경된 icd stat 신호전달을 갖는 cd122 |
| CN115315273A (zh) * | 2020-01-14 | 2022-11-08 | 辛德凯因股份有限公司 | Il-2直向同源物及其使用方法 |
| PE20221757A1 (es) | 2020-02-24 | 2022-11-11 | Allogene Therapeutics Inc | Celulas t con car de bcma con actividades mejoradas |
| US20230138428A1 (en) * | 2020-02-25 | 2023-05-04 | Quell Therapeutics Limited | Chimeric receptors for use in engineered cells |
| US20230121433A1 (en) * | 2020-03-11 | 2023-04-20 | Poseida Therapeutics, Inc. | Chimeric stimulatory receptors and methods of use in t cell activation and differentiation |
| IL298279A (en) * | 2020-04-17 | 2023-01-01 | Council Queensland Inst Medical Res | Immune cells with enhanced function |
| EP4136231A1 (en) * | 2020-04-17 | 2023-02-22 | Friedrich Miescher Institute for Biomedical Research | Use of an orphan motif to increase expression of a heterologous transgene |
| EP4139345A1 (en) * | 2020-04-24 | 2023-03-01 | Sorrento Therapeutics, Inc. | Memory dimeric antigen receptors |
| KR102297396B1 (ko) | 2020-07-29 | 2021-09-06 | (주)티카로스 | 면역시냅스를 안정화시키는 키메라 항원 수용체(car) t 세포 |
| US12012441B2 (en) | 2020-10-26 | 2024-06-18 | Neptune Biosciences Llc | Engineered human IL-21 cytokines and methods for using the same |
| US20250270320A1 (en) | 2020-12-10 | 2025-08-28 | Eutilex Co., Ltd. | Anti-pd-1 antibody and uses thereof |
| CN114716548B (zh) | 2021-01-05 | 2024-11-05 | (株)爱恩德生物 | 抗-fgfr3抗体及其用途 |
| CN113512125B (zh) * | 2021-04-26 | 2024-01-19 | 北京双赢科创生物科技有限公司 | 一种携带stat结合基序的嵌合抗原受体分子及表达该嵌合抗原受体分子的nk细胞 |
| EP4402161A1 (en) | 2021-09-17 | 2024-07-24 | Parker Institute For Cancer Immunotherapy | Switch receptors using il-9 signaling domains |
| WO2023158997A2 (en) * | 2022-02-15 | 2023-08-24 | Memorial Sloan-Kettering Cancer Center | Compositions including killer innate-like t cells and uses therof |
| US20250154463A1 (en) * | 2022-02-15 | 2025-05-15 | Memorial Sloan-Kettering Cancer Center | Compositions including cytotoxic innate lymphoid cells and uses thereof |
| EP4554972A1 (en) * | 2022-07-11 | 2025-05-21 | The Board of Trustees of the Leland Stanford Junior University | Tunable cytokine receptor signaling domains |
| IL318546A (en) | 2022-07-26 | 2025-03-01 | Aimed Bio Inc | Anti-ROR1 antibody and its uses |
| EP4342907A1 (en) | 2022-09-21 | 2024-03-27 | AvenCell Europe GmbH | Switchable chimeric antigen receptors and their use |
| AU2023353989A1 (en) | 2022-09-30 | 2025-02-27 | Caribou Biosciences, Inc. | Anti-ror1 chimeric antigen receptors (cars), cells expressing the cars and related methods |
| EP4633648A1 (en) * | 2022-12-15 | 2025-10-22 | Carisma Therapeutics Inc. | Chimeric antigen receptors including jak/stat binding domains and modified immune cells |
| WO2025096673A1 (en) * | 2023-10-30 | 2025-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions comprising cells targeting cancer and methods of using the same |
| WO2026006794A1 (en) * | 2024-06-27 | 2026-01-02 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric antigen receptors and uses thereof |
| WO2026024468A1 (en) | 2024-07-26 | 2026-01-29 | Caribou Biosciences, Inc. | Modular linked chimeric antigen receptors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
| US5837544A (en) * | 1995-02-02 | 1998-11-17 | Cell Genesys, Inc. | Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase |
| US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| EP1795599A1 (en) | 2005-12-09 | 2007-06-13 | Schuler, Gerold, Prof. Dr. | Methods for generating antigen-specific effector T cells |
| WO2008042814A2 (en) | 2006-09-29 | 2008-04-10 | California Institute Of Technology | Mart-1 t cell receptors |
| WO2010089412A1 (en) | 2009-02-09 | 2010-08-12 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof |
| WO2012154858A1 (en) | 2011-05-09 | 2012-11-15 | Whitehead Institute For Biomedical Research | Chaperone interaction assays and uses thereof |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| EP2997134B1 (en) * | 2013-05-14 | 2020-06-24 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| CA2913052A1 (en) * | 2013-05-24 | 2014-11-27 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| CA2974998C (en) | 2015-02-12 | 2022-04-26 | Takara Bio Inc. | Chimeric antigen receptors |
-
2016
- 2016-02-11 CA CA2974998A patent/CA2974998C/en active Active
- 2016-02-11 EP EP16748518.4A patent/EP3256496B1/en active Active
- 2016-02-11 US US15/550,645 patent/US10336810B2/en active Active
- 2016-02-11 WO PCT/CA2016/050126 patent/WO2016127257A1/en not_active Ceased
- 2016-02-11 ES ES16748518T patent/ES2857998T3/es active Active
- 2016-02-11 JP JP2017541919A patent/JP6846352B2/ja active Active
- 2016-02-11 KR KR1020177025120A patent/KR102607152B1/ko active Active
-
2019
- 2019-05-14 US US16/411,941 patent/US10822392B2/en active Active
-
2020
- 2020-11-06 JP JP2020186004A patent/JP2021036883A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024138280A5 (enExample) | ||
| JP7198670B2 (ja) | 免疫調整性ｉｌ２ｒ融合タンパク質およびその使用 | |
| JP2022109953A5 (enExample) | ||
| JP2021536249A5 (enExample) | ||
| JP2018523484A5 (enExample) | ||
| AU2023206126C1 (en) | TGF-β receptors and methods of use | |
| JP7466231B2 (ja) | キメラ抗原受容体及びその適用 | |
| JP2019517267A5 (enExample) | ||
| JP2017515464A5 (enExample) | ||
| US20190055318A1 (en) | Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy | |
| CN112771167A (zh) | 表达有趋化因子的细胞及用途 | |
| JP2018532407A5 (enExample) | ||
| JP2019513394A5 (enExample) | ||
| Rubinstein et al. | Transfer of TCR genes into mature T cells is accompanied by the maintenance of parental T cell avidity | |
| JP2021516049A (ja) | 組換えｔ細胞受容体遺伝子を用いて細胞ベースの治療薬を製造するための技法 | |
| WO2025213573A1 (zh) | 细胞免疫疗法的组合物和方法 | |
| CN119301150A (zh) | 人工免疫受体 | |
| CN111875712A (zh) | 一种增强型靶向muc1的嵌合抗原受体及其应用 | |
| WO2025031441A1 (en) | Engineered cells expressing trimeric complexes | |
| JP2015223143A (ja) | Ｔｃｒの細胞傷害活性誘導能を評価するためのｎｋ細胞株、およびその作製方法 | |
| TWI790162B (zh) | 新穎t細胞受器及使用其之免疫治療 | |
| EP4653455A1 (en) | Mutated pd1 ectodomain fragment and car containing same, and nk cell | |
| CN115820697B (zh) | 一种免疫细胞及其制备方法和应用 | |
| US20260015397A1 (en) | Chimeric membrane-bound cytokines incorporating costimulatory elements for enhancing anti-inflammatory function | |
| US20220233596A1 (en) | Modified NK-92 cells, and therapeutic and diagnostic uses thereof |